Did You Know?

Editor’s Picks

Latest News

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy

Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) aloneNORCROSS, Ga., April...

Capital Senior Living Completes Third Round of COVID-19 Vaccinations at All Communities and Reports March Occupancy

DALLAS, April 13, 2021 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (the “Company”) (NYSE: CSU) has completed first, second and third rounds of COVID-19 vaccinations at all its communities. To...

eClinicalWorks’ Solution Helping Providers Schedule COVID-19 Appointments and Administer Vaccines Across 29 States

eClinicalWorks' Vaccine Administration Management Solution aids healthcare providers with efficient, effective, and HIPAA-compliant COVID-19 vaccine distribution WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, a...

error: Content is protected !!